ライフサイエンスコーパス: combined modality therapy

1 of these toxicities may be accentuated with combined modality therapy.

2 astic breast cancer xenografts were cured by combined modality therapy.

3 rapy trials not suited to define the role of combined-modality therapy.

4 ations were the only predictors of receiving combined-modality therapy.

5 ardizing the excellent outcome obtained with combined-modality therapy.

6 n therapy, 26 with chemotherapy, and 16 with combined-modality therapy.

7 cantly more likely to undergo surgery and/or combined-modality therapy.

8 on of patients who receive all components of combined modality therapy and avoids the toxicity of pan

9 urative treatment because of improvements in combined modality therapy and development of new techniq

10 ies, the majority of these patients received combined modality therapy and were treated with modern r

11 luded assessment of toxicity associated with combined-modality therapy and initial assessment of the

12 field size (P =.03) in patients who received combined modality therapy, and with time after Hodgkin d

13 Only 39% received combined-modality therapy, and this proportion significa

14 ring preoperative and postoperative adjuvant combined modality therapy are ongoing.

15 th either alkylating agents alone (n = 1) or combined modality therapy (CMT) (n = 4).

16 with rectal cancer treated with preoperative combined modality therapy (CMT) followed by total mesore

17 Recent studies have shown that preoperative combined modality therapy (CMT) for rectal cancer enhanc

18 ond the gross tumor margin after neoadjuvant combined modality therapy (CMT) for rectal cancer.

19 To determine whether combined modality therapy (CMT) is superior to chemother

20 f therapy, whereas 80 of 161 were to receive combined modality therapy (CMT).

21 The choice between combined-modality therapy (CMT) and chemotherapy alone f

22 has evolved from radiotherapy alone (RT) to combined-modality therapy (CMT) because of concerns abou

23 nty of the 154 patients received neoadjuvant combined-modality therapy (CMT) consisting of concurrent

24 ther subtotal lymphoid irradiation (STLI) or combined-modality therapy (CMT) consisting of three cycl

25 protocols have evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive blad

26 Although combined-modality therapy (CMT) is the preferred treatme

27 nt of rectal cancer response to preoperative combined-modality therapy (CMT) using digital rectal exa

28 adigms for elderly patients with GBM include combined-modality therapy (CMT) with both radiotherapy (

29 a-aortic (MPA) radiotherapy was favored over combined-modality therapy (CMT), mantle radiotherapy, an

30 s for pediatric patients treated for HD with combined-modality therapy (CMT).

31 Current combined modality therapies confer a significant risk of

32 erapy administered with curative intent, ie, combined-modality therapy consisting of chemotherapy, su

33 e, and histology, were randomized to receive combined-modality therapy consisting of four monthly cyc

34 The addition of rituximab (S0014) to combined-modality therapy did not mitigate the continued

35 hown that acute relapse rates are lower with combined modality therapy, even in patients with negativ

36 Combined modality therapy for non-small-cell lung cancer

37 Combined modality therapy for PCNSL has improved surviva

38 tify children at high risk for relapse after combined-modality therapy for Hodgkin's disease.

39 late pelvic toxicity for patients completing combined-modality therapy for invasive bladder cancer an

40 pronounced in the elderly patients receiving combined-modality therapy for locally advanced NSCLC.

41 Utility of combined-modality therapy for patients with limited-stag

42 Preoperative combined-modality therapy for rectal cancer may allow fo

43 Assessment of long-term results of combined-modality therapy for resectable non-small-cell

44 s of brain metastases in patients undergoing combined-modality therapy for stage III non-small-cell l

45 Two months after the administration of combined-modality therapy for stage IIIA non-small cell

46 Esophagitis was common during combined modality therapy (grade 3, 10 patients; grade 4

47 te treatment morbidity, randomized trials of combined-modality therapy have been conducted demonstrat

48 reatment of astrocytic tumors, which include combined modality therapy, have been empirically derived

49 had pulmonary function adequate to withstand combined-modality therapy, identical to the requirements

50 distant metastatic disease and sparing them combined-modality therapy), improved radiation technique

51 in 27 patients, radiation therapy in 28, and combined modality therapy in 46.

52 efficacy of single-agent therapy but also of combined modality therapy in gliomas.

53 Abandonment of combined-modality therapy in favor of chemotherapy alone

54 incorporate novel antiangiogenic agents into combined-modality therapy in lung cancer are needed.

55 ignant diseases and patients treated without combined-modality therapy in other studies.

56 nd were randomized to receive a preoperative combined-modality therapy including fluorouracil and rad

57 A possible role for combined modality therapy, including combination chemoth

58 Unlike many other tumor types, combined modality therapy involving radiation and chemot

59 This paclitaxel-containing combined modality therapy is feasible and highly active

60 Combined-modality therapy is feasible and associated wit

61 ar determinants of apoptosis associated with combined modality therapy may guide the design of more e

62 Interventions Combined modality therapy (n = 134): 50 Gy in 25 fractio

63 significantly over the last two decades with combined-modality therapy now the standard of care.

64 For the use of combined modality therapy of chemoradiation, random assi

65 er, the impact of FO-enriched nutrition as a combined modality therapy on clinical outcomes remains c

66 or patients who underwent radiation therapy, combined-modality therapy, or chemotherapy, the recurren

67 The benefit of combined-modality therapy over radiation therapy alone i

68 lone, and 82% and 64% for patients receiving combined-modality therapy (P < .001).

69 vanced NSCLC should be encouraged to receive combined-modality therapy, preferably on clinical trials

70 Combined-modality therapy quality, survival, and safety

71 onsored, randomized, postoperative, adjuvant combined modality therapy rectal cancer trials into curr

72 s of outcomes in elderly patients argue that combined modality therapy should be considered, with pat

73 randomized trials of chemotherapy alone vs. combined-modality therapy, suggest that chemotherapy alo

74 r enhancement of apoptosis in the setting of combined modality therapy than when administered with ei

75 dvanced disease in which despite advances in combined modality therapy the outcomes have not dramatic

76 has evolved over the last two decades, with combined-modality therapy the current standard of care.

77 ured with sphincter-preserving, nonsurgical, combined-modality therapy, those with large tumors and l

78 atients with muscle-invasive bladder cancer, combined-modality therapy (transurethral resection bladd

79 groups have resulted in the use of adjuvant combined modality therapy using radiation therapy and 5-

80 Risk-adapted, combined-modality therapy using only four cycles of VAMP

81 Risk-adapted, combined-modality therapy using VAMP chemotherapy with r

82 Combined modality therapy, using surgery, radiation ther

83 patients with negative interim FDG-PET/CT to combined modality therapy versus chemotherapy alone have

84 year survival rate in patients who underwent combined modality therapy was 23%.

85 ting for immortal times and indication bias, combined-modality therapy was associated with better OS

86 The combined-modality therapy was well tolerated, but DLT pr

87 Current data demonstrate that combined modality therapy with early administration of t

88 Combined modality therapy with paclitaxel, carboplatin,

89 dy was to determine the optimum sequence for combined modality therapy with radiolabeled antibodies a

90 Combined modality therapy with TURBT, chemotherapy, radi

91 treatment with FU and cisplatin followed by combined-modality therapy with FU, mitomycin C, and conc

92 ssion-free survival, and overall survival of combined-modality therapy with PAC plus radiation therap

93 patients who developed late metachronous OS, combined-modality therapy with surgery and aggressive ch

94 Risk-adapted combined-modality therapy with VAMP/COP and response-bas

95 Combined-modality therapy with VEPA chemotherapy and low

96 Combined-modality therapy, with chemotherapy and cystect